Pharmacokinetics of intravenous chlorzoxazone in rats with dehydration and rehydration: Effects of food intakes

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 2, 2003, Pages 53-61

  Kim, Yu C ^a   Kim, Yoon G ^a   Kim, Eun J ^a   Cho, Min K ^a   Kim, Sang G ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

Chlozoxazone and 6 hydroxychlorzoxazone; CYP2E1; Pharmacokinetics; Rats with dehydration and rehydration

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; DRUG METABOLITE; GLUCURONIDE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; FOOD DRUG INTERACTION; FOOD INTAKE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REHYDRATION; TISSUE DISTRIBUTION; URINARY EXCRETION; WATER DEPRIVATION;

ANIMALS; AREA UNDER CURVE; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEHYDRATION; EATING; INJECTIONS, INTRAVENOUS; MALE; MUSCLE RELAXANTS, CENTRAL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; WATER DEPRIVATION;

EID: 0037340367     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.335     Document Type: Article

References (24)

1. Baker SK, Niazi S. Effect of water deprivation on aspirin disposition kinetics. J Pharm Sci 1983; 72: 1030-1034.
2. Kim SH, Kwon JW, Kim WB, Lee I, Lee MG. Effects of water deprivation for 72 hours on the pharmacokinetics of a new carbapenem, DA-1131, in rats. Life Sci.
3. Tanaka E, Kurata N, Kuroiwa Y, Misawa S. Influence of short-term water deprivation on kinetics of trimethadione and its metabolite in rats. Jpn J Pharmacol 1986; 42: 269-274.
4. Kim SG, Kim EJ, Kim YG, Lee MG. Expression of cytochrome P-450s and glutathione S-transferases in the rat liver during water deprivation: effects of glucose supplementation. J Appl Toxicol 2001; 21: 123-129.
5. Ma Q, Dannan GA, Guengerich FP, Yang CS. Similarities and differences in the regulation of hepatic cytochrome P-450 enzymes by diabetes and fasting in male rats. Biochem Pharmacol 1989; 38: 3179-3184.
6. Chen L, Yang CS. Effects of cytochrome P4502E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorazoxazone in rats. Life Sci 1996; 58: 1575-1585.
7. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 1990; 3: 566-573.
8. Conney AH, Burns JJ. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J Pharmacol Exp Ther 1960; 128: 340-343.
9. Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983; 72: 991-994.
10. Rockich K, Blouin R. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 1999; 27: 1074-1077.
11. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B 1996; 686: 291-296.
12. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
13. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
14. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel Dekker: New York, 1982.
15. Chiou WL. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 1980; 69: 90-91.
16. Chiou WL. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
17. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
18. Lee HJ, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 1989; 6: 833-839.
19. Lee HJ, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm Res 1989; 6: 840-843.
20. Osman SA, Smith JD, Hanson LE, Meade RJ. The conservation of water by young adult rats with restricted water supplies. J Nutr 1966; 90: 268-274.
21. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5: 143-150.
22. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997; 27: 243-256.
23. Shimada T, Tsumura F, Yamazaki H. Prediction of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 1999; 27: 1274-1280.
24. Carriere V, Goasduff T, Ratanasavanh D, et al., Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993; 6: 852-857.